Hearing loss is the most common symptom in patients with vestibular schwannoma (VS). In the past, compressive mechanisms caused by the tumoral mass and its growth have been regarded as the most likely causes of the hearing loss associated with VS. Interestingly, new evidence proposes molecular mechanisms as an explanation for such hearing loss. Among the molecular mechanisms proposed are methylation of TP73, negative expression of cyclin D1, expression of B7-H1, increased expression of the platelet-derived growth factor A, underexpression of PEX5L, RAD54B, and PSMAL, and overexpression of CEA. Many molecular mechanisms are involved in vestibular schwannoma development; we review some of these mechanisms with special emphasis on hearing loss associated with vestibular schwannoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335540 | PMC |
| http://dx.doi.org/10.1155/2012/856157 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Angiotensin-Receptor Blockers Prevent Vestibular Schwannoma-Associated Hearing Loss.
Otol Neurotol
February 2025
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Background Introduction: Vestibular schwannoma (VS) tumors typically present with sensorineural hearing loss (SNHL). Losartan has recently demonstrated prevention of tumor-associated SNHL in a mouse model of VS through suppression of inflammatory and pro-fibrotic factors, and the current study investigates this association in humans.
Methods: This is a retrospective study of patients with unilateral VS and hypertension followed with sequential audiometry at a tertiary referral hospital from January 1994 to June 2023.
Use of Hearing Aids Embedded with Inertial Sensors and Artificial Intelligence to Identify Patients at Risk for Falling.
Otol Neurotol
February 2025
Department of Otolaryngology-Head and Neck Surgery.
Objective: To compare fall risk scores of hearing aids embedded with inertial measurement units (IMU-HAs) and powered by artificial intelligence (AI) algorithms with scores by trained observers.
Study Design: Prospective, double-blinded, observational study of fall risk scores between trained observers and those of IMU-HAs.
Setting: Tertiary referral center.
Effects of spectral manipulations of music mixes on musical scene analysis abilities of hearing-impaired listeners.
PLoS One
January 2025
Dept. of Medical Physics and Acoustics, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.
Music pre-processing methods are currently becoming a recognized area of research with the goal of making music more accessible to listeners with a hearing impairment. Our previous study showed that hearing-impaired listeners preferred spectrally manipulated multi-track mixes. Nevertheless, the acoustical basis of mixing for hearing-impaired listeners remains poorly understood.
View Article and Find Full Text PDFHypothetical criteria and types for cochlear migraine.
Medicine (Baltimore)
January 2025
Department of Otolaryngology-Head and Neck Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
Cochlear migraine (CM) and cochleovestibular migraine were first reported in 2018. However, the diagnostic criteria and types of CM were still undefined. We proposed a hypothetical criteria for CM as below: A.
View Article and Find Full Text PDFHearing loss in patients with Morquio A syndrome: A scoping review.
Medicine (Baltimore)
January 2025
Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras (CIACER), Universidad Iccesi, Cali, Colombia.
Background: Hearing impairment is a prevalent clinical feature in Morquio syndrome (mucopolysaccharidosis IVA or MPS IVA) patients, often presenting in diverse forms: conductive, sensorineural, or a combination known as mixed hearing loss. The mixed form entails a blend of both conductive and sensorineural elements, typically exhibiting a progressive trajectory. This scoping review aimed to comprehensively analyze available evidence pertaining to the pathophysiology, classification, epidemiology, and clinical management of hearing loss in individuals with MPS IVA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!